Navigation Links
Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
Date:6/17/2009

NEW YORK, June 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that the Company has received a letter from The NASDAQ Stock Market confirming that it has regained compliance with the minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2) and that the matter is now closed.

The Company also received a letter from the NASDAQ Listing Qualifications Hearings Panel confirming that it has demonstrated a market value of listed securities over the required minimum of $35 million for 10 consecutive trading days, for continued listing on The NASDAQ Capital Market under Listing Rule 5550(b)(2), and that the Panel has determined to continue the listing of the Company's securities on The NASDAQ Stock Market.

The Company's stock continues to be listed on the NASDAQ Capital Market and its ticker symbol of KERX remains unchanged.

"We are pleased to have regained compliance with all the NASDAQ Capital Market listing requirements," stated Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals. "We believe this represents an important step in building value for our stockholders."

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KR
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
3. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
4. Keryx Biopharmaceuticals Receives Nasdaq Notification
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
6. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
10. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
11. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... from healthy, unrelated donors was safe and effective ... by Clostridium difficile , according to a ... Diseases and available online. Known as fecal ... given via a colonoscope or a nasogastric tube. ... promising treatment more readily available to patients. , ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... WEST LAFAYETTE, Ind. - Purdue University researchers have developed ... a living cell by using tiny gold particles with ... Irudayaraj, professor of agricultural and biological engineering, used gold ... material known as BRCA1 messenger RNA splice variants, which ... The number of these mRNA splice variants in a ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... person's face could unveil whether he or she is a ... smokers.A study by dermatologists, published in The Lancet, shows that ... breaks down collagen in the skin.// ,Collagen is the ... of the skin. When this starts to deteriorate, skin begins ...
... devised that each cigarette cuts on average 12 minutes off ... difference in life expectancy between smokers and non-smokers and an ... smoker might consume in a lifetime. ,The researchers, from ... from a major study of the impact of// smoking carried ...
... of drinks is a common problem for heavy drinkers and ... until now.It may support the potentialities of a night out. ... and the Mayo Clinic in Minnesota say the effect of ... in a study of healthy young adults, that blood vessels ...
... descendants of females who are given a choice to select ... the choice.The research involves the humble fruit fly, but experts ... ,Geneticists from the University of Georgia, led by Dr ... fruit fly, in a vial with one virgin female.// Some ...
... patients who are undergoing androgen deprivation therapy by ... New York Cornell Medical Center say this non ... monotherapy in men who require long-term antiandrogen therapy.//, ... patients with clinically localised prostate cancer and 24 ...
... still a health problem need to ensure their people understand ... Organization (WHO) has said. Partners in WHO's Global Alliance for ... annual meeting. Brazil is one of six countries in the ... others are India, Madagascar, Mozambique, Myanmar and Nepal. ...
Cached Medicine News:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... has revolutionized healthcare and is essential in the detection ... protocols ensure that patients, physicians, and technicians are exposed ... providing accurate results and diagnostic information. ... be balanced with the benefits of that procedure. Alarmist ...
... Muscular Dystrophy Association ( MDA ) has awarded $750,000 to ... development of an experimental drug that may become a viable ... The funding comes from MDA Venture Philanthropy (MVP), ... is one of nine types of muscular dystrophy, a group ...
Cached Medicine Technology:AAPM Cautions that Patients Should Not Forgo Essential Medical Imaging 2MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 2MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 3MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 4
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Round solid lower plate. Open upper plate with inside diameter 15 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Medicine Products: